Dec 19, 2025 • MarketBeat
NEUTRAL
Clover Health Investments, Corp. (NASDAQ:CLOV) Given Consensus Recommendation of "Hold" by Analysts
Clover Health Investments, Corp. (NASDAQ:CLOV) has received a consensus "Hold" recommendation from analysts, with an average 12-month price target of $3.23. The company recently missed EPS expectations but exceeded revenue forecasts, while institutional investors have adjusted their positions in the stock. CLOV shares are currently trading around $2.64 with a market capitalization of $1.36 billion.
Dec 15, 2025 • MarketBeat
SOMEWHAT-BEARISH
Rhumbline Advisers Increases Position in Clover Health Investments, Corp. $CLOV
Rhumbline Advisers significantly increased its stake in Clover Health Investments (NASDAQ:CLOV) by 8,149.2% in the second quarter, now holding 584,459 shares valued at $1.63 million. Despite this increased institutional interest, analysts maintain a "Hold" consensus rating with a target price of $3.93, while the company faces challenges with missed EPS estimates and negative profitability metrics. Several other institutional investors also acquired new positions in CLOV during recent quarters, indicating varied sentiment towards the stock.
Dec 11, 2025 • MarketBeat
NEUTRAL
Soviero Asset Management LP Acquires 650,000 Shares of Clover Health Investments, Corp. $CLOV
Soviero Asset Management LP significantly increased its stake in Clover Health Investments, Corp. (NASDAQ:CLOV) by 260%, acquiring an additional 650,000 shares to total 900,000 shares worth approximately $2.51 million. Despite a recent EPS miss, the company reported revenue of $496.65 million, surpassing expectations. Analysts currently have a "Hold" consensus rating for CLOV, with an average price target of $3.93.
Nov 23, 2025 • MarketBeat
SOMEWHAT-BULLISH
Clover Health Investments, Corp. (NASDAQ:CLOV) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Clover Health Investments, Corp. (NASDAQ:CLOV) has received a "Moderate Buy" consensus recommendation from six analysts, with an average 12-month price target of $3.93. The company recently reported a quarterly EPS of ($0.05), missing estimates, but revenue beat expectations at $496.65 million. Institutional investors have been increasing their stakes, and the stock currently trades around $2.28.
Nov 21, 2025 • Quiver Quantitative
SOMEWHAT-BULLISH
Clover Health's CFO Peter Kuipers to Present at 2025 Citi Global Healthcare Conference
Clover Health's CFO, Peter Kuipers, is scheduled to present at the 2025 Citi Global Healthcare Conference on December 4, 2025. The presentation will discuss the company's focus on improving healthcare access for Medicare beneficiaries through its Clover Assistant software platform. This engagement aims to increase investor visibility and highlight Clover Health's technological advancements and commitment to enhancing patient outcomes.
Nov 19, 2025 • Yahoo Finance
SOMEWHAT-BULLISH
Clover Health Investments, Corp. (CLOV) Reports Break-Even Earnings for Q3
Clover Health Investments (CLOV) reported break-even quarterly earnings, surpassing the Zacks Consensus Estimate of a $0.02 loss per share for Q3 2025, and also exceeded revenue expectations with $496.65 million. The company has shown favorable estimate revisions recently, earning a Zacks Rank #2 (Buy), suggesting potential market outperformance. This positive outlook is supported by a 16.8% stock gain year-to-date, slightly outpacing the S&P 500.